FP receptor instrumental in upregulation of matrix metalloproteinase

Article

Topical latanoprost (Xalatan, Pfizer Ophthalmics) upregulates matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, and FP receptor gene expression in the mouse sclera. These responses are critically dependent on an intact FP receptor gene, said John Crowston, MD, University of Melbourne, Center for Eye Research Australia, East Melbourne, Australia.

Topical latanoprost (Xalatan, Pfizer Ophthalmics) upregulates matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, and FP receptor gene expression in the mouse sclera. These responses are critically dependent on an intact FP receptor gene, said John Crowston, MD, University of Melbourne, Center for Eye Research Australia, East Melbourne, Australia.

"Prostaglandin alpha analogues bind the prostaglandin FP receptor and have been shown to induce long-term stable reduction of IOP in humans and primates," Dr. Crowston said. "The prostaglandins are thought to do so by increasing uveoscleral outflow, probably by reducing extracellular matrix protein and by relaxing the ciliary muscle."

He also explained that prostaglandin-mediated upregulation of MMPs has been demonstrated in cell culture models and in vivo in various animal models.

"MMPs are endopeptidases that degrade extracellular matrix, and there is evidence of this [with] in vitro cell culture models of human ciliary muscles," Dr. Crowston said. "The FP receptor is a critical component in the MMP upregulation. However, the role of the MMP receptor in MMP gene upregulation in vivo is not well understood."

Dr. Crowston and colleagues conducted a study to determine changes in MMP expression over time. Wild-type mice were treated once daily with 200 mg of topical latanoprost. Scleral and retinal tissues were harvested after 2 hours and 1, 3, and 7 days of treatment; pooled MMP mRNA was quantified and compared with untreated control eyes. To assess the role of the FP receptor, FP knockout and wild-type littermate controls were treated daily for 7 days and MMP expression was determined in the sclera and retina and compared with untreated fellow eyes.

He reported that MMP-2, MMP-3, MMP-9, and FP mRNA were upregulated in the sclera, with peak expression at day 7 of treatment. There was no upregulation of these genes in the retina. In addition, in FP receptor knockout mice, there was no increase in MMP gene expression in the sclera compared with the untreated fellow eyes. Significant increases in MMP gene expression were observed in the wild-type littermates with intact FP receptors.

"A fully intact FP receptor seems to be necessary for the latanoprost-mediated MMP-2, MMP-3, and MMP-9 upregulation in the mouse eye in vivo," Dr. Crowston concluded.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.